Seastar Medical Holding Corporation · NASDAQ:ICU
Seastar Medical — Investor Presentation (August 2026)
26 slides from Seastar Medical's investor presentation, August 2026
Slide 1: Investor Presentation
Investor Presentation Transforming treatments for critically ill patients facing organ failure and potential loss of life. August 2026 www.SeaStarMedical.com Nasdaq: ICU
Slide 2: Forward-looking statements
2 Forward-looking statements This presentation contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1955. These forward-looking statements include, without limitation, SeaStar Medical’s expectations with re
Slide 3: Our Mission
3 Our Mission Stop organ failure Expand indications and Maximize market Drive stakeholder Save lives areas of treatment penetration value Destructive hyperinflammation FDA Breakthrough Device First and ONLY therapy High gross profit margin and leads to organ failure and loss Designations awarded for
Slide 4: First indications in pediatric and adult AKI provide significant market opportunity
4 First indications in pediatric and adult acute kidney injury (AKI) provide significant market opportunity for our SCD therapy UPDATE: High unmet need in adult AKI CMS has assigned ICD-10-PCS codes effective as of October 1, 2026: Mortality rates for critically ill Adult AKI total US 50%+ patients
Slide 5: Patient Outcome: Permanent Organ Damage or Death
5 THE PROBLEM: Hyperinflammatory response can lead to multi-organ damage and death Infection / Innate Immune Dysregulated immune response End-Organ Injury Response (hyperinflammation) Damage Activated monocytes • Pulmonary infiltrates • Lung injury • Acute respiratory distress syndrome Other • Cardi
Slide 6: THE SOLUTION: SCD therapy targets upstream source of effector cells
6 THE SOLUTION: SCD therapy targets upstream source of effector cells and neutralizes effector cells that release cytokines Other drugs and therapies that focus on individual downstream QUELIMMUNE inflammatory targets such as IL-6, TNF-⍺ etc. fail to address the high redundancy in the immune system
Slide 7: Unique mechanism of action of the SCD restores reparative physiology
7 Unique mechanism of action of the SCD restores reparative physiology LOWER ionized calcium SCD to venous in circuit with citrate Venous return line return line Ca2+ replacement Standard venous return line (renal therapy standard-of- Selectively TARGET highly care) Ionized Ca2+ activated neutrophil
Slide 8: Launched first commercial product and executing on a robust pipeline
8 Launched first commercial product and executing on a robust pipeline Indication Investigational Feasibility study Pivotal trial Approved Approved under a QUELIMMUNE: Humanitarian Device Pediatric AKI Q1’24 Exemption.* Launched in July 2024 Pipeline Indications: SCD-ADULT indications require minim
Slide 9: QUELIMMUNE addresses a high unmet need in pediatric AKI
9 QUELIMMUNE addresses a high unmet need in pediatric AKI Despite advances in supportive treatments, pediatric patients with AKI often deteriorate due to untreated hyperinflammation 27% 2x 50% ≥30% ICU A DM IS S IONS LO NGER IN ICU M OR TA LITY CH RON IC DIS EA S E Overall incidence Patients with A
Slide 10: QUELIMMUNE clinical data supporting FDA approval in pediatric AKI
10 QUELIMMUNE clinical data supporting FDA approval in pediatric AKI QUELIMMUNE* Standard of Care 77% Survival1 At Day 60 50% NO Dialysis dependency2 At Day 60 (Post-ICU Discharge) 10% to 30% Device-related NO Immunosuppression, serious adverse events or infections Activated neutrophil * Pooled data
Slide 11: Additional data from the SAVE Surveillance Registry mirror high survival rates
11 Additional data from the Save Surveillance Registry mirror high survival rates from clinical data The SAVE Surveillance Registry is assessing the use of the QUELIMMUNE therapy in the treatment of critically ill pediatric patients with life- threatening AKI and sepsis or septic condition requiring
Slide 12: Safety Profile of SCD therapy across adult & pediatric AKI studies
12 Safety Profile of SCD therapy across 6 adult & pediatric AKI studies • No device-related infections, immunosuppression or SAEs across >150 patients • >50% of these patients were septic Total SCD Study # # SCD Treated # SCD Used per # Device-Related # Device-Related Total # SCD Used Exposure Time
Slide 13: Focused commercial strategy to drive early adoption
13 Focused commercial strategy to drive early adoption Adoption by 20 Key elements of our commercial Top-Tier U.S. strategy: Pediatric Children's • Focus on top academic sites first to Hospitals create brand recognition and treatment experience 50 hospitals • Target early adopters: ~20% of top 50 Fi
Slide 14: Adoption of QUELIMMUNE by Top-Rated Children's Hospitals
14 Adoption of QUELIMMUNE by Top-Rated Children’s Hospitals
Slide 15: QUELIMMUNE provides value to a hospital's bottom line
15 QUELIMMUNE provides value to a hospital’s bottom line
Slide 16: Adult AKI study outcomes consistent with pediatric studies
16 Adult AKI study outcomes consistent with pediatric studies Survival at Day 60 Dialysis Dependence at Day 60 Pediatric AKI Adult AKI Adult Adult 90% 90% Adult AKI Historical Pediatric AKI Historical Control Control 80% 80% 70% 70% % Dialysis Dependence Day 60 60% 60% 50% % Survival Day 60 50% 50%
Slide 17: Pivotal trial underway in adult AKI
17 Pivotal trial underway in adult AKI Assess the safety & efficacy of SCD in patients with AKI requiring continuous renal Trial Objective replacement therapy (CRRT) SCD Therapy + CRRT Randomized 1:1 N = Up to 339 Patients need to be on CRRT for ≥ and meet I/E criteria CRRT Control Primary Endpoint:
Slide 18: NEUTRALIZE-AKI pivotal trial gaining momentum
18 NEUTRALIZE-AKI pivotal trial gaining momentum • 223 of up to 339 subjects enrolled (>65% to date)* University of Cincinnati • 20 medical sites activated • Mix of academic, military, and community hospitals • CMS reimbursement for Methodist Hospital Main Medicare/Medicaid patients ⎻ Reduces trial
Slide 19: Third potential indication for patients with chronic systolic heart failure
19 Third potential indication for patients with chronic systolic heart failure awaiting LVAD* or heart transplant Assess the safety & efficacy of SCD patients with chronic systolic heart failure complicated by Trial Objective cardiorenal syndrome (CRS) who are not candidates for heart transplant or
Slide 20: SCD pipeline – approach to clinical development
20 SCD pipeline – approach to clinical development: Scientific, cost-effective, medical-community focused Engage and Drive the Science Publications and Presentations University of Chaired by David Michigan Humes, MD, SCD inventor, Professor, research Division of Nephrology - Research grants Scientif
Slide 21: Seasoned, dynamic leadership
21 Seasoned, dynamic leadership ERIC SCHLORFF MIKE MESSINGER KEVIN CHUNG, MD SAI IYER, PHD TOM MULLEN TIM VARACEK CEO and Board Chief Financial Officer Chief Medical Officer SVP, Medical Affairs SVP, Manufacturing SVP, Commercial Member and Clinical and Product Business Development Development Op
Slide 22: Capital structure and financial position
22 Capital structure and financial position Ticker Symbol ICU Market Capitalization * ~$15.0 million Shares Outstanding ** 4.4 million Warrants Outstanding*** 2.7 million Cash**** ~$7.0 million Long-term Debt Zero * Based on recent share price ** Approximate shares outstanding 8/12/26 and reflects a
Slide 23: Catalysts to drive value creation
23 Catalysts to drive value creation Add 15 new customers to the QUELIMMUNE customer base Complete enrollment in NEUTRALIZE-AKI QUELIMMUNE launch expansion: 10 pivotal trial around YE ’26 / Q1’27 hospitals ordering product Awarded FDA Breakthrough Designation for Chronic Dialysis Advance clinical de
Slide 24: Our Mission
24 Our Mission Stop organ failure Expand indications and Maximize market Drive stakeholder Save lives areas of treatment penetration value Destructive hyperinflammation FDA Breakthrough Device First and ONLY therapy High gross profit margin and leads to organ failure and loss Designations awarded fo
Slide 25: Investment Highlights
25 Investment Highlights Best-in-class Commercializing first NEUTRALIZE-AKI Multibillion-dollar technology indication pivotal trial in progress market • Clinically proven to reduce • FDA approval for pediatric • Achieved 223* of 339 • Potential application in mortality acute kidney injury with patie
Slide 26: Investor Presentation
Investor Presentation Transforming treatments for critically ill patients facing organ failure and potential loss of life. August 2026 www.SeaStarMedical.com Nasdaq: ICU Investor Contact: IR@SEASTARMED.COM
SeaStar Medical Holding — Investor Presentation (August 2026) on 6ix